The University of Connecticut has granted MAKScientific an exclusive license to a variety of compounds active in the endocannabinoid pathways.  Through this strategic agreement, MAKScientific has acquired a large and growing portfolio of novel compounds that target CB1 and CB2 receptors, fatty acid amide hydrolase (FAAH) and monoacyl glycerol lipase (MGL).  These compounds have been advanced for the treatment of chronic liver disease, metabolic disorders, neuropathic and inflammatory pain, addiction, and neuroprotection.

A large portfolio of patent applications covering the compounds described has already been filed with several patents issued or granted.  Our lead CB1 neutral antagonist (AM6545) and several backup compounds have been described in PCT/US2009/001054. Additional CB1 receptor antagonists have been disclosed in PCT/US2006/000720 and PCT/US2008/007257.